TNFRSF10B and non-small cell lung carcinoma: PARAs such as dulanermin (rhTRAIL), mapatumumab (anti-DR4 mAb), conatumumab, CS-1008, or PRO95780 (anti-DR5 mAb), in combination with paclitaxel, carboplatin, or bevacizumab [anti-vascular endothelial growth factor (VEGF) mAb] were tested for their effects toward NSCLC patients in a randomized phase II trial, but showed only modest effects (11).